SipNose focuses on nose-to-brain medical applications and is developing a nasal delivery platform for local, systemic, and central nervous system indications. The company’s intranasal drug-delivery platform uses a mechanism designed to improve efficacy, patient compliance, and safety.
SipNose’s noninvasive devices are designed to ensure accurate dose delivery via the nasal cavity and incorporate a simple, efficient mechanism to allow localization of the aerosolized drug in the olfactory epithelium, resulting in better absorption into the olfactory bulb and brain.
The company’s technology enables drug molecules of vast chemical and pharmaceutical characteristics to reach the brain faster and more efficiently with higher safety and improved patient experience.
Cumulative Funding Raised Over Time ($)
Employees Over Time
SipNose Climate Tech relevance
null
Latest News
No Data, yet.
Sorry, no content found under this section.
Oct 9, 2024
en.globes.co.il
Aptar Pharma buys Israeli drug delivery co SipNose
#Acquired-by
Jun 1, 2021
www.businesswire.com
Noveome Biotherapeutics, Inc. and SipNose, Ltd. Announce Commercial License Agreement for SipNose Cribriform Targeted Device